Health systems are being squeezed by ageing populations, overstretched health professionals, unsustainable costs and a failure to tackle disease prevention – and a new way
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh